Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Fintel reports that on December 19, 2025, HC Wainwright & Co. maintained coverage of Werewolf Therapeutics (NasdaqGS:HOWL) ...

As of Friday, December 19, Werewolf Therapeutics, Inc.’s HOWL share price has surged by 9.05%, which has investors questioning if this is right time to sell.

These miniatures are new sculpts for the Sinbad collection and have been crafted by the hand of Mark Evans. Some brilliant characters for those seeking to play out some classic Fantasy adventures on ...

As of Thursday, December 18, Werewolf Therapeutics, Inc.’s HOWL share price has dipped by 41.36%, which has investors questioning if this is right time to buy.

On December 18, 2025, Werewolf Therapeutics reported a pipeline update and 2026 business priorities centered on its INDUKINE and INDUCER platforms, highlighting preliminary clinical data and a shift ...

WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI ...

Extras' or 'background actors' are there to help fill out a scene, with these roles usually having minimal to no lines.

Former 10% owners of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) including MPM Asset Management LLC, MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM Oncology Innovations Fund LP, Oncology ...

Find more insights and a comprehensive research report on HOWL in InvestingPro, covering over 1,400 US equities. In other recent news, Werewolf Therapeutics, Inc. has received Fast Track Designation ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL) between December 2nd and December 4th, 2025. The sales, executed under a prearranged 10b5-1 trading plan, totaled ...